Allarity Therapeutics (NASDAQ:ALLR) stock is heading higher on Friday alongside heavy pre-market trading.
Investors will note that this movement comes after the company announced a prospectus supplement. This alters the maximum aggregate offering price of shares sold through prospectus from $1,350,000 to $2,350,000.
Allarity Therapeutics notes that it currently has 828,580 shares outstanding with a value of $7,092,593. The amendment mentions that the company has sold $1,348,908 worth of its shares and is eligible to sell $1,015,290 more.
ALLR Stock Movement Today
Due to heavy pre-market trading, more than 2.8 million shares of the clinical-stage biopharmaceutical company’s stock changed hands. That’s well above its daily average trading volume of about 59,000 shares.
Investors will also note that ALLR stock is up 41.3% as of Friday morning. Even so, the shares closed out Thursday down 78.9% since the start of the year.
Another thing to note is that ALLR is a penny stock. This comes from its low daily average trading volume, a prior closing price of $2.30 per share and a market capitalization of only $1.0821.082. All of these make it a risky investment.
There are even more of the most recent stock market stories traders will want to read about today below!
We are offering all of the hottest stock market news that investors need to know about on Friday! Among that is what has shares of PaxMedica (NASDAQ:PXMD) stock rising, the biggest pre-market stock movers this morning and more. All of this info is ready to go at the following links!
More Stock Market News for Friday
- Why Is PaxMedica (PXMD) Stock Up 93% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
- 5 Investors Betting Big on Rent the Runway (RENT) Stock
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
